Carvykti (ciltacabtagene autoleucel)

News alerts, weekly reports and conference planners

Company:

J&J, Legend Biotech

Drug class:

BCMA-targeted CAR-T immunotherapy

Related drugs:

›

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	ciltacabtagene autoleucel Sensitive: A1 - Approval ciltacabtagene autoleucel Sensitive : A1	ciltacabtagene autoleucel Sensitive: A1 - Approval ciltacabtagene autoleucel Sensitive : A1
TNFRSF17 overexpression	Multiple Myeloma	TNFRSF17 overexpression	Multiple Myeloma	ciltacabtagene autoleucel Sensitive: C3 – Early Trials ciltacabtagene autoleucel Sensitive : C3	ciltacabtagene autoleucel Sensitive: C3 – Early Trials ciltacabtagene autoleucel Sensitive : C3

Associations
(2)